Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap53.92B
Enterprise Value80.22B
Trailing P/E45.69
Forward P/E25.40
TAK
(NYSE)Takeda Pharmaceutical Company Limited
$16.82-- (--)
Loading... - Market loading
Takeda Pharmaceutical Company (TAK) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)1.94
Forward Price/Sales1.96
Price/Book (mrq)1.13
Price/FCF (ttm)10.88
Price/OCF (ttm)8.95
PEG Ratio0.58
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue2.89
EV/Earnings67.98
EV/EBITDA10.04
EV/EBIT28.89
EV/FCF16.19
Stock Price
Current price, 52-week range, and moving averages
Current Price$16.82
1-Day Change-0.30%
52-Week High$18.90
52-Week Low$12.99
52-Week Change14.11%
YTD Change7.68%
1-Year Change14.73%
50-Day MA$16.18
200-Day MA$16.18
Avg Volume (30 day)3.23M
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding3.21B
Book Value per Share$14.88
Net Cash per Share$-8.20
FCF per Share$1.55
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Analyst ConsensusBuy
Analyst Count1
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin58.47%
EBITDA Margin (ttm)28.75%
EBIT Margin (ttm)10.00%
Operating Margin (ttm)13.11%
Pretax Margin (ttm)5.75%
Profit Margin (ttm)4.25%
FCF Margin (ttm)17.84%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)2.47%
Return on Assets (ttm)1.24%
Return on Invested Capital (ttm)2.77%
Return on Capital Employed (ttm)3.48%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue27.78B
Gross Profit16.24B
Operating Income3.64B
Pretax Income1.60B
Net Income1.18B
EBITDA7.99B
EBIT2.78B
Diluted EPS$0.37
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow6.03B
Capital Expenditures1.07B
Free Cash Flow4.96B
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth0.17%
Dividend Growth44.26%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)94.80B
Cash & Securities (mrq)3.65B
Net Cash (mrq)-26.30B
Net Cash per Share$-8.20
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)29.95B
Working Capital (mrq)4.05B
Total Equity (mrq)47.69B
Book Value per Share$14.88
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)1.27
Quick Ratio (mrq)0.70
Debt/Equity (mrq)0.63
Debt/EBITDA (ttm)3.75
Debt/FCF (ttm)6.04
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.97
Dividend Yield5.76%
Payout Ratio (Earnings)200.00%
Payout Ratio (FCF)62.71%
Dividend Growth (YoY)44.26%
Years of Dividend Growth3
Ex-Dividend DateMar 31, 2027
Pay DateMar 31, 2027
Dividend FrequencySemi-Annual
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield2.19%
FCF Yield9.19%
Buyback Yield98.16%
Total Shareholder Yield103.92%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score1.76
Piotroski F-Score5/9
Dividend Score58.46
Fair Value & Intrinsic Value
Lynch fair value, Graham number, and valuation models
Lynch Fair Value$31.27
Lynch Upside/Downside85.92%
Graham Number$11.13
Graham Upside/Downside-33.84%
Frequently Asked Questions About Takeda Pharmaceutical Company Statistics
What are the key financial metrics for TAK?
Takeda Pharmaceutical Company Limited (TAK) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is TAK's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Takeda Pharmaceutical Company is overvalued or undervalued.
How do I read TAK's profitability ratios?
Takeda Pharmaceutical Company's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do TAK's debt ratios indicate?
The financial health section shows Takeda Pharmaceutical Company's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is TAK's dividend analysis?
The dividend section covers Takeda Pharmaceutical Company's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.